Serum Autoantibodies in Patients with Dry and Wet Age-Related Macular Degeneration
Journal of Clinical Medicine · 17.02.2023 · 12 (4) · 1590
DOI: 10.3390/jcm12041590 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.02.2023. Verfasst von Christina A Korb und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma GmbH, Germany, Novartis Pharma GmbH, Nürnberg, Germany.
Abstract (Originalsprache)
Background
To assess the serum autoantibody profile in patients with dry and exudative age-related macular degeneration compared with healthy volunteers to detect potential biomarkers, e.g., markers for progression of the disease. Materials and Methods: IgG Immunoreactivities were compared in patients suffering from dry age-related macular degeneration (AMD) (n = 20), patients with treatment-naive exudative AMD (n = 29) and healthy volunteers (n = 21). Serum was analysed by customized antigen microarrays containing 61 antigens. The statistical analysis was performed by univariate and multivariate analysis of variance, predictive data-mining methods and artificial neuronal networks were used to detect specific autoantibody patterns.
Results
The immunoreactivities of dry and wet AMD patients were significantly different from each other and from controls. One of the most prominently changed reactivity was against alpha-synuclein (p ≤ 0.0034), which is known from other neurodegenerative diseases. Furthermore, reactivities against glyceraldehyde-3-phosphat-dehydrogenase (p ≤ 0.031) and Annexin V (p ≤ 0.034), which performs a major role in apoptotic processes, were significantly changed. Some immunoreacitvities were antithetic regulated in wet and dry-AMD, such as Vesicle transport-related protein (VTI-B).
Conclusions
Comparison of autoantibody profiles in patients with dry and wet AMD revealed significantly altered immunoreactivities against proteins particularly found in immunological diseases, further neurodegenerative, apoptotic and autoimmune markers could be observed. A validation study has to explore if these antibody pattern can help to understand the underlying differences in pathogenesis, evaluate their prognostic value and if those could be possibly useful as additional therapeutic targets.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany.
ORCID-Profile: Christina A Korb, Katrin Lorenz
Förderung
- Novartis Pharma GmbH, Germany
- Novartis Pharma GmbH, Nürnberg, Germany
Zitieren
APA
Korb, C. A., Beck, S., Wolters, D., Lorenz, K., Pfeiffer, N., & Grus, F. H. (2023). Serum Autoantibodies in Patients with Dry and Wet Age-Related Macular Degeneration. Journal of Clinical Medicine, 12(4), 1590. https://doi.org/10.3390/jcm12041590
Vancouver
Korb CA, Beck S, Wolters D, Lorenz K, Pfeiffer N, Grus FH. Serum Autoantibodies in Patients with Dry and Wet Age-Related Macular Degeneration. Journal of Clinical Medicine. 2023;12(4):1590. doi:10.3390/jcm12041590
BibTeX
@article{Korb2023,
author = {Korb, Christina A and Beck, Sabine and Wolters, Dominik and Lorenz, Katrin and Pfeiffer, Norbert and Grus, Franz H},
title = {Serum Autoantibodies in Patients with Dry and Wet Age-Related Macular Degeneration},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {1590},
doi = {10.3390/jcm12041590}
}
EUVIMED